September 22, 2021Open Access

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Nathan et al. (Wed,) studied this question.

synapsesocial.com/papers/69d96fcf5e5bcb4e3b8366df https://doi.org/https://doi.org/10.1056/nejmoa2103485

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types2019 · 106 citations
2ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells2018 · 3,397 citations
3Tumor Mutational Burden and Response Rate to PD-1 Inhibition2017 · 3,312 citations
4Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,600 citations
5Molecular pathology of uveal melanoma2012 · 181 citations

Bookmark

View Full Paper